Answer
Secukinumab’s mean elimination half-life in plaque psoriasis patients was 27 days, estimated by population pharmacokinetic analysis, ranging from 18 to 46 days across psoriasis studies with intravenous administration.
Sources for this answer
- Cosentyx 150mg and 300mg solution for injection in pre-filled syringe and pre-filled penNovartis Pharmaceuticals UK Ltd · emc · SmPC §5.2 Pharmacokinetic properties · Version 29Document updated
Sources checked